BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11159177)

  • 1. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.
    Hing S; Lu YJ; Summersgill B; King-Underwood L; Nicholson J; Grundy P; Grundy R; Gessler M; Shipley J; Pritchard-Jones K
    Am J Pathol; 2001 Feb; 158(2):393-8. PubMed ID: 11159177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of chemotherapy on the cytogenetic constitution of Wilms' tumor.
    Schlomm T; Gunawan B; Schulten HJ; Sander B; Thangavelu K; Graf N; Leuschner I; Ringert RH; Füzesi L
    Clin Cancer Res; 2005 Jun; 11(12):4382-7. PubMed ID: 15958621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain of 1q is a marker of poor prognosis in Wilms' tumors.
    Segers H; van den Heuvel-Eibrink MM; Williams RD; van Tinteren H; Vujanic G; Pieters R; Pritchard-Jones K; Bown N;
    Genes Chromosomes Cancer; 2013 Nov; 52(11):1065-74. PubMed ID: 24038759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.
    Natrajan R; Williams RD; Hing SN; Mackay A; Reis-Filho JS; Fenwick K; Iravani M; Valgeirsson H; Grigoriadis A; Langford CF; Dovey O; Gregory SG; Weber BL; Ashworth A; Grundy PE; Pritchard-Jones K; Jones C
    J Pathol; 2006 Sep; 210(1):49-58. PubMed ID: 16823893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
    Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
    Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
    Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
    Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines.
    Williams RD; Hing SN; Greer BT; Whiteford CC; Wei JS; Natrajan R; Kelsey A; Rogers S; Campbell C; Pritchard-Jones K; Khan J
    Genes Chromosomes Cancer; 2004 Sep; 41(1):65-79. PubMed ID: 15236318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased microvascular density predicts relapse in Wilms' tumor.
    Abramson LP; Grundy PE; Rademaker AW; Helenowski I; Cornwell M; Katzenstein HM; Reynolds M; Arensman RM; Crawford SE
    J Pediatr Surg; 2003 Mar; 38(3):325-30; discussion 325-30. PubMed ID: 12632343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of limited regions of genetic aberrations in patients affected with Wilms' tumor using a tiling-path chromosome 22 array.
    Benetkiewicz M; Díaz de Ståhl T; Gördör A; Pfeifer S; Wittmann S; Gessler M; Dumanski JP
    Int J Cancer; 2006 Aug; 119(3):571-8. PubMed ID: 16496407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative genomic hybridization and its application to Wilms' tumorigenesis.
    Getman ME; Houseal TW; Miller GA; Grundy PE; Cowell JK; Landes GM
    Cytogenet Cell Genet; 1998; 82(3-4):284-90. PubMed ID: 9858837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Der(16)t(1;16)(q21;q13) in Wilms' tumor: friend or foe.
    Mathew P; Douglass EC; Jones D; Valentine M; Valentine V; Rowe S; Shapiro DN
    Med Pediatr Oncol; 1996 Jul; 27(1):3-7. PubMed ID: 8614388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.
    Natrajan R; Reis-Filho JS; Little SE; Messahel B; Brundler MA; Dome JS; Grundy PE; Vujanic GM; Pritchard-Jones K; Jones C
    Cancer Res; 2006 Dec; 66(23):11148-55. PubMed ID: 17145858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
    Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
    Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phyllodes tumors of the breast analyzed by comparative genomic hybridization and association of increased 1q copy number with stromal overgrowth and recurrence.
    Lu YJ; Birdsall S; Osin P; Gusterson B; Shipley J
    Genes Chromosomes Cancer; 1997 Nov; 20(3):275-81. PubMed ID: 9365835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
    Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
    J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.
    Natrajan R; Little SE; Sodha N; Reis-Filho JS; Mackay A; Fenwick K; Ashworth A; Perlman EJ; Dome JS; Grundy PE; Pritchard-Jones K; Jones C
    J Pathol; 2007 Jan; 211(1):52-9. PubMed ID: 17103382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.